

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**April 6, 2022 (~~April 5, 2022~~)**  
Date of Report (Date of earliest event reported)

**DENTSPLY SIRONA Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**0-16211**  
(Commission File Number)

**39-1434669**  
(I.R.S. Employer Identification No.)

**13320 Ballantyne Corporate Place,**  
(Address of Principal Executive Offices)

**Charlotte**

**North Carolina**

**28277-3607**  
(Zip Code)

**(844) 848-0137**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	<b>XRAY</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective April 5, 2022, DENTSPLY SIRONA Inc. (the “Company”) appointed Mr. John Groetelaars to the Board of Directors of the Company (the “Board”) and expanded the size of the Board from eleven members to twelve members. The Board has determined that Mr. Groetelaars qualifies as an independent director for purposes of the rules of The Nasdaq Stock Market as well as applicable rules and regulations adopted by the Securities and Exchange Commission (“SEC”). There are no transactions, per Item 404(a) of Regulation S-K, between the Company and Mr. Groetelaars, his former employer, or any of his family members for the last fiscal year and the current fiscal year to date. Mr. Groetelaars will participate in the same compensation plans as the other non-employee members of the Board, as described under “Directors’ Compensation” in the Company’s preliminary proxy statement filed with the SEC on April 1, 2022 for its 2022 annual meeting of stockholders. Mr. Groetelaars’ Committee assignments will be determined at a later date.

**Item 7.01 Regulation FD Disclosure.**

On April 6, 2022, the Company issued a press release announcing the appointment of Mr. Groetelaars. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in Items 7.01 and 9.01 to this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

Exhibit No. Description

[99.1](#) DENTSPLY SIRONA Inc. press release, dated April 6, 2022  
104 Cover Page Interactive Date File (embedded within the Inline XBRL Document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.

By: /s/ Cherée Johnson  
Cherée Johnson  
Executive Vice President - Chief Legal  
Officer, General Counsel and Secretary

Date: April 6, 2022

## Dentsply Sirona Announces Appointment of Mr. John P. Groetelaars as New Board Member

## Press Contact

**Dentsply Sirona, the world's largest manufacturer of professional dental products and technologies, today announced that Mr. John P. Groetelaars has been appointed to its Board of Directors.**

Charlotte, NC. April 6, 2022. DENTSPLY SIRONA Inc. ("Dentsply Sirona") (Nasdaq: XRAY) today announced that Mr. John P. Groetelaars has been appointed to its Board of Directors (the "Board"), increasing the size of its Board from eleven to twelve members.

"We are pleased to welcome John Groetelaars to the Dentsply Sirona Board of Directors." said Eric K. Brandt, Non-Executive Chairman of the Board. "John brings more than 20 years of international experience, including as the former CEO of Hillrom. John's deep medical technology experience and leadership roles will be a valuable addition to our Board of Directors. We look forward to working with him as we continue to advance patient care through high-quality and innovative dental solutions."

Mr. John P. Groetelaars served as President, CEO and a Board member at Hillrom from May 2018 until the company's acquisition by Baxter International, Inc., in December 2021. At Hillrom, he had enterprise responsibility for a global healthcare technology company with \$3 billion in revenue and more than 10,000 employees. Mr. Groetelaars led a transformation of Hillrom's business, successfully articulating and launching a new connected-care strategy and vision, growing the portfolio through seven acquisitions and one divestiture, and driving record financial performance. In addition, he championed and actively led diversity, inclusion, equity and belonging initiatives across the company, which led to record levels of employee engagement, and external recognition from DiversityInc, Forbes and many other organizations. Prior to Hillrom, Mr. Groetelaars served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company, a medical technology company, since December 2017 following its acquisition of C.R. Bard Inc., a medical technology company, where his responsibilities included global strategic, financial, operational and innovation platforms. He previously served in a variety of progressive roles at C.R. Bard during his 10-year career there, including as a group president from 2015 to 2017. Mr. Groetelaars joined C.R. Bard in 2008 as vice president and general manager, Davol Inc., and was appointed president of Davol in 2009. In 2013, Mr. Groetelaars was promoted to group vice president and in 2015 he was promoted to group president, a position he held until C.R. Bard was acquired by Becton, Dickinson and Company in December 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions in Canada, Denmark and the United Kingdom at Boston Scientific Corporation from 2001 until 2008. Prior to joining Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business

About Dentsply Sirona:  
Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona's products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarter is located in Charlotte, North Carolina. The company's shares are listed in the United States on NASDAQ under the symbol XRAY.

Visit [www.dentsplysirona.com](http://www.dentsplysirona.com) for more information about Dentsply Sirona and its products.

development and sales with Guidant Corporation and with Eli Lilly. He currently serves as a director of the AdvaMed board and is a member of The Economic Club of Chicago.

## IMAGES

are available at > [Download](#)





